FDA allows continued sale of generic Opana painkiller

The agency determined that a newer version of the drug was not better at deterring abuse

The Food and Drug Administration (FDA) announced Friday that it will allow the continued sale of generic forms of the prescription pain drug Opana ER, after the agency found that a new form of the drug was not significantly more successful at preventing abuse.

Opana, which is manufactured by Endo Health Solutions, is an extended-release narcotic. These types of drugs are popular among addicts, who crush the pills in an effort to snort or inject the full dose all at once.

Alanna Byrne

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.